Senti Biosciences (SNTI) Receivables (2021 - 2025)
Senti Biosciences' quarterly Receivables came in at $500000.0 in Q4 2025, down 69.62% year-on-year from $1.6 million in Q4 2024, and down 68.75% quarter-over-quarter from $1.6 million in Q3 2025.
Senti Biosciences has reported Receivables for 5 years, with the latest figure at $500000.0 in Q4 2025.
- For the quarter ending Q4 2025, Receivables fell 69.62% year-over-year to $500000.0; the trailing twelve-month figure through Dec 2025 stood at $500000.0 (down 69.62% YoY), and the FY2025 full-year result was $500000.0, down 69.62% from the prior year.
- Receivables for Q4 2025 stood at $500000.0, down from $1.6 million in the prior quarter.
- The five-year high for Receivables was $17.6 million in Q4 2023, with the low at $39000.0 in Q2 2024.
- Average Receivables over 5 years is $2.2 million, with a median of $900000.0 recorded in 2024.
- Year-over-year, Receivables plunged 93.12% in 2024 and surged 8935.9% in 2025.
- Tracing SNTI's Receivables over 5 years: stood at $483000.0 in 2021, then jumped by 75.16% to $846000.0 in 2022, then jumped by 1979.43% to $17.6 million in 2023, then tumbled by 90.64% to $1.6 million in 2024, then slumped by 69.62% to $500000.0 in 2025.
- The last three Receivables figures came in at $500000.0 (Q4 2025), $1.6 million (Q3 2025), and $3.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 500,000.00 |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 3.52 Mn |
| Mar 31, 2025 | 2.09 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 39,000.00 |
| Mar 31, 2024 | 900,000.00 |
| Dec 31, 2023 | 17.59 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 567,000.00 |
| Mar 31, 2023 | 791,000.00 |
| Sep 30, 2022 | 846,000.00 |
| Jun 30, 2022 | 573,000.00 |
| Dec 31, 2021 | 483,000.00 |